Primary Tumor Location as a Prognostic Factor in Meta

Journal of the National Cancer Institute
107,
DOI: 10.1093/jnci/dju427

Citation Report

#	Article	IF	Citations
1	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
2	Metastatic Colorectal Cancer: Review of Diagnosis and Treatment Options. Jurnalul De Chirurgie, 2015, 10, .	0.0	4
3	RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, djv207.	3.0	3
5	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology, 2015, 28, 1390-1399.	2.9	53
6	Rectal and colon cancer: Not just a different anatomic site. Cancer Treatment Reviews, 2015, 41, 671-679.	3.4	239
7	How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). Current Colorectal Cancer Reports, 2015, 11, 151-159.	1.0	2
8	RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, djv203.	3.0	10
9	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. OncoTargets and Therapy, 2016, 9, 1899.	1.0	44
10	Differential Radiographic Appearance ofBRAFV600Eâ€“Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1536-1543.	2.3	17
11	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology, 2016, 9, 1091-1108.	1.3	9
12	PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. BMC Cancer, 2016, 16, 366.	1.1	18
13	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	1.9	94
14	The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. Journal of Surgical Oncology, 2016, 114, 803-809.	0.8	73
15	Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 303-313.	1.0	0
16	Does tumor side represent a relevant factor for prognosis and treatment decision in metastatic colorectal cancer?. Colorectal Cancer, 2016, 5, 91-93.	0.8	1
17	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer, 2016, 114, 1352-1361.	2.9	81
18	Tumor-Infiltrating Lymphocytes, Crohnâ€™s-Like Lymphoid Reaction, and Survival From Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	3.0	162
19	Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. International Journal of Molecular Medicine, 2016, 37, 319-328.	1.8	12

#	Article	IF	Citations
20	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15.	1.0	45
21	The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Surgery, 2016, 20, 648-655.	0.9	209
22	Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics Journal, 2017, 17, 258-264.	0.9	79
23	First-line therapy for mCRC â€" the influence of primary tumour location on the therapeutic algorithm. Nature Reviews Clinical Oncology, 2017, 14, 113-113.	12.5	35
24	Colorectal cancer statistics, 2017. Ca-A Cancer Journal for Clinicians, 2017, 67, 177-193.	157.7	3,300
25	What roles do colon stem cells and gap junctions play in the left and right location of origin of colorectal cancers?. Journal of Cell Communication and Signaling, 2017, 11, 79-87.	1.8	8
26	Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. European Journal of Surgical Oncology, 2017, 43, 1040-1049.	0.5	18
27	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Annals of Oncology, 2017, 28, 1713-1729.	0.6	654
28	Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology, 2017, 28, 1862-1868.	0.6	174
29	The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. European Journal of Cancer, 2017, 70, 87-98.	1.3	436
30	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. British Journal of Cancer, 2017, 117, 315-321.	2.9	19
31	Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 411-419.	2.3	261
32	Impact of cap-assisted colonoscopy on detection of proximal colon adenomas: systematic review and meta-analysis. Gastrointestinal Endoscopy, 2017, 86, 274-281.e3.	0.5	31
33	From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 235-246.	12.5	466
34	Current and future biomarkers in the treatment of colorectal cancer. Acta Clinica Belgica, 2017, 72, 103-115.	0.5	30
35	Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Annals of Oncology, 2017, 28, 562-568.	0.6	132
36	Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia. Oncology, 2017, 92, 75-86.	0.9	16
37	Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer. Annals of Surgical Oncology, 2017, 24, 1269-1280.	0.7	52

#	Article	IF	Citations
39	KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Scientific Reports, 2017, 7, 14368.	1.6	13
40	Nerve/Glial Antigen 2: A Novel Target for Anti-Tumor Therapy in Colorectal Cancer. Digestion, 2017, 96, 60-66.	1.2	2
41	Precision Oncology: Present Status and Perspectives. Current Clinical Pathology, 2017, , 7-26.	0.0	0
42	Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 551-564.	1.4	82
43	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. European Journal of Cancer, 2017, 84, 69-80.	1.3	212
44	KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010â€“2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1484-1493.	2.3	39
45	Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncology Letters, 2017, 14, 453-460.	0.8	24
46	Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer. JAMA Oncology, 2017, 3, 211.	3.4	544
47	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics Journal, 2017, 17, 543-550.	0.9	11
48	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	3.4	555
49	Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials. Clinical Colorectal Cancer, 2017, 16, e171-e180.	1.0	40
51	Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. Journal of Cancer, 2017, 8, 388-394.	1.2	24
52	Current and future biomarkers in colorectal cancer. Annals of Gastroenterology, 2017, 30, 613-621.	0.4	88
53	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. International Journal of Molecular Sciences, 2017, 18, 1240.	1.8	38
54	The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement. Current Oncology, 2017, 24, 390-400.	0.9	8
55	A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients. PLoS ONE, 2017, 12, e0172799.	1.1	16
56	Is There a Sex Effect in Colon Cancer? Disease Characteristics, Management, and Outcomes in Routine Clinical Practice. Current Oncology, 2017, 24, 15-23.	0.9	23
57	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	0.8	147

#	Article	IF	Citations
58	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en CancÃ©rologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	0.8	37
59	Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget, 2017, 8, 52403-52412.	0.8	49
60	Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget, 2017, 8, 93567-93579.	0.8	26
61	Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Review of Anticancer Therapy, 2018, 18, 351-358.	1.1	60
63	Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status. Clinical Cancer Research, 2018, 24, 2548-2558.	3.2	14
64	The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis. European Journal of Surgical Oncology, 2018, 44, 771-777.	0.5	36
65	Impact of Right-sided Primary Tumor Location Among Patients With Oligometastatic Colorectal Cancer Treated With Stereotactic Body Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1172-1175.	0.6	0
66	What Chemotherapy to Recommend in Metastatic Patients?. , 2018, , 339-348.		0
67	Biomarkers in colorectal liver metastases. British Journal of Surgery, 2018, 105, 618-627.	0.1	59
68	The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 125, 69-77.	2.0	17
69	The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. British Journal of Cancer, 2018, 118, 705-712.	2.9	46
70	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	1.1	41
71	Perioperative dynamics and significance of plasma-free amino acid profiles in colorectal cancer. BMC Surgery, 2018, 18, 11.	0.6	8
72	UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2018, 82, 87-98.	1.1	12
73	D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer. International Journal of Clinical Oncology, 2018, 23, 689-697.	1.0	26
74	The prognostic implications of primary tumor location on recurrence in early-stage colorectal cancer with no associated risk factors. International Journal of Colorectal Disease, 2018, 33, 719-726.	1.0	9
75	Clinical Trials and Progress in Metastatic Colon Cancer. Surgical Oncology Clinics of North America, 2018, 27, 349-365.	0.6	64
76	Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort. Journal of Gastrointestinal Cancer, 2018, 49, 124-131.	0.6	10

#	Article	IF	Citations
77	Impact of Primary Tumor Location on Postoperative Recurrence and Subsequent Prognosis in Nonmetastatic Colon Cancers. Annals of Surgery, 2018, 267, 917-921.	2.1	39
78	Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. Annals of Surgery, 2018, 267, 514-520.	2.1	59
79	Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer. JAMA Surgery, 2018, 153, 60.	2.2	37
80	DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene, 2018, 37, 566-577.	2.6	65
81	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research, 2018, 24, 1062-1072.	3.2	225
82	Colorectal Cancers Developed from Proximal and Distal Tumor Location Belong to theÂDistinct Genetic Entity and Show Different Oncologic Behavior. Current Human Cell Research and Applications, 2018, , 81-91.	0.1	0
83	Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e201-e206.	1.0	17
84	The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2018, 121, 1-10.	2.0	45
85	Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 778-784.	0.6	13
86	Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel dropletâ€embedded drug sensitivity test. Oncology Letters, 2019, 17, 1842-1850.	0.8	6
87	Prognostic effect of sidedness in early stage versus advanced colon cancer. Health Science Reports, 2018, 1, e54.	0.6	11
88	Recent advances in understanding colorectal cancer. F1000Research, 2018, 7, 1528.	0.8	14
89	Plasma metabolomic profiling distinguishes right-sided from left-sided colon cancer. Clinica Chimica Acta, 2018, 487, 357-362.	0.5	17
90	DNA mismatch repair and CD133-marked cancer stem cells in colorectal carcinoma. PeerJ, 2018, 6, e5530.	0.9	7
91	Primary tumor location in stage III colon cancer has prognostic impact on subsequent liver metastasis. Journal of Surgical Oncology, 2018, 118, 1301-1310.	0.8	10
92	Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Management and Research, 2019, Volume 11, 359-368.	0.9	8
93	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	2.9	19
94	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Management and Research, 2018, Volume 10, 5895-5908.	0.9	18

#	Article	IF	Citations
95	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	1.3	13
96	Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterology Research, 2018, 11, 264-273.	0.4	294
97	Different Anatomical Subsites of Colon Cancer and Mortality: A Population-Based Study. Gastroenterology Research and Practice, 2018, 2018, 1-9.	0.7	11
98	What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?. Current Colorectal Cancer Reports, 2018, 14, 175-183.	1.0	0
99	To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 132, 154-160.	2.0	5
100	Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology, 2018, 13, 735-743.	1.7	6
101	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	1.5	61
102	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	1.3	21
103	Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Japanese Journal of Clinical Oncology, 2018, 48, 609-618.	0.6	40
104	Differences between carcinoma of the cecum and ascending colon: Evidence based on clinical and embryological data. International Journal of Oncology, 2018, 53, 87-98.	1.4	5
105	Colorectal Cancer: Why Does Side Matter?. Drugs, 2018, 78, 789-798.	4.9	41
106	Individualized predictive signatures for 5â€fluorouracilâ€based chemotherapy in rightâ€and leftâ€sided colon cancer. Cancer Science, 2018, 109, 1939-1948.	1.7	13
107	Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical Oncology, 2018, 35, 101.	1.2	6
108	Primary Tumor Location in Colorectal Cancer: Comparison of Right- and Left-Sided Colorectal Cancer Characteristics for the Interventional Radiologist. CardioVascular and Interventional Radiology, 2018, 41, 1819-1825.	0.9	6
109	Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions. Journal of Surgical Research, 2018, 232, 72-81.	0.8	19
110	Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Frontiers in Immunology, 2018, 9, 1578.	2.2	143
111	Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. European Journal of Cancer, 2018, 101, 105-113.	1.3	19
112	Identification of genomic expression differences between right-sided and left-sided colon cancer based on bioinformatics analysis. OncoTargets and Therapy, 2018, Volume 11, 609-618.	1.0	14

#	Article	IF	Citations
113	Calcitriol Supplementation Causes Decreases in Tumorigenic Proteins and Different Proteomic and Metabolomic Signatures in Right versus Left-Sided Colon Cancer. Metabolites, 2018, 8, 5.	1.3	7
114	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. British Journal of Cancer, 2018, 119, 303-312.	2.9	29
115	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open, 2018, 3, e000403.	2.0	20
116	Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. BMC Cancer, 2018, 18, 752.	1.1	29
117	The effect of epidural analgesia on cancer progression in patients with stage IV colorectal cancer after primary tumor resection: A retrospective cohort study. PLoS ONE, 2018, 13, e0200893.	1.1	19
118	First-line molecular therapies in the treatment of metastatic colorectal cancer â€“ a literature-based review of phases II and III trials. Innovative Surgical Sciences, 2018, 3, 85-86.	0.4	6
119	Molecular Variances Between Right- and Left-sided Colon Cancers. Current Colorectal Cancer Reports, 2018, 14, 152-158.	1.0	5
120	Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. Clinical Colorectal Cancer, 2018, 17, e733-e739.	1.0	7
121	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist, 2019, 24, 319-326.	1.9	29
122	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications, 2019, 10, 3722.	5.8	131
123	ASO Author Reflections: Prognostic Impact of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 666-667.	0.7	1
124	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. Drugs in R and D, 2019, 19, 267-275.	1.1	4
126	Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer. , 2019, , .		2
127	Neurexophilin and PCâ€esterase domain family member 4 (NXPE4) and prostate androgenâ€regulated mucinâ€like protein 1 (PARM1) as prognostic biomarkers for colorectal cancer. Journal of Cellular Biochemistry, 2019, 120, 18041-18052.	1.2	13
128	Clinicopathological features and phenotypic classification of de novoâ€type colorectal carcinomas differ from those of colorectal carcinomas derived from flat adenomas. Pathology International, 2019, 69, 331-340.	0.6	10
129	Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2019, 9, 723.	1.3	13
130	Correlation of Tumor Location to Clinical Outcomes in Colorectal Cancer: A Single-institution Retrospective Analysis. Anticancer Research, 2019, 39, 4917-4924.	0.5	6
131	The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. Anticancer Research, 2019, 39, 5645-5652.	0.5	9

#	Article	IF	Citations
132	Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. Journal of Cancer, 2019, 10, 388-396.	1.2	4
133	A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer. BMC Genomics, 2019, 20, 769.	1.2	5
134	Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update. Future Oncology, 2019, 15, 3149-3157.	1.1	8
135	Validation of diagnosis codes to identify side of colon in an electronic health record registry. BMC Medical Research Methodology, 2019, 19, 177.	1.4	16
136	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. Scientific Reports, 2019, 9, 11527.	1.6	13
137	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	1.8	17
138	Systemic Therapy for Advanced and Metastatic Colon Cancer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 73, 202.	0.2	1
139	The Clinical Significance of Microsatellite Instability in Patients with Right-sided Colorectal Cancer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 73, 159.	0.2	3
140	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 2019, 37, 1876-1885.	0.8	169
141	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Annals of Surgical Oncology, 2019, 26, 2234-2240.	0.7	16
142	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	5.1	362
143	Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. Annals of Surgical Oncology, 2019, 26, 1421-1427.	0.7	18
144	Colon Cancer Sidedness, Presentation, and Survival at Different Stages. Journal of Oncology, 2019, 2019, 1-12.	0.6	43
145	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer, 2019, 18, 116-124.	1.0	7
146	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. Scientific Reports, 2019, 9, 3668.	1.6	7
147	Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study. Clinical and Translational Oncology, 2019, 21, 1524-1531.	1.2	32
148	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs, 2019, 79, 633-645.	4.9	32
149	Update on systemic therapy for colorectal cancer: biologics take sides. Translational Gastroenterology and Hepatology, 2019, 4, 9-9.	1.5	22

#	Article	IF	Citations
150	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	2.0	14
151	Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study. Annals of Surgical Oncology, 2019, 26, 1358-1365.	0.7	27
152	The Developing Story of Predictive Biomarkers in Colorectal Cancer. Journal of Personalized Medicine, 2019, 9, 12.	1.1	111
153	Selective Internal Radiation Therapy in the Multidisciplinary Management of Liver Metastases From Colorectal Carcinoma. Seminars in Nuclear Medicine, 2019, 49, 182-188.	2.5	7
154	Firstâ€line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-14.	0.7	4
155	Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 136-143.	0.7	12
156	Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist, 2019, 24, 921-932.	1.9	51
157	Another Chapter of the Right Versus Left Story : Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. Oncologist, 2019, 24, e77-e79.	1.9	3
158	Serum extracellular vesicles contain SPARC and LRG1 as biomarkers of colon cancer and differ by tumour primary location. EBioMedicine, 2019, 50, 211-223.	2.7	51
159	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	1.2	24
160	Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas. Annals of Surgery, 2021, 274, e126-e133.	2.1	19
161	Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy. Medicine (United States), 2019, 98, e14326.	0.4	5
162	MicroRNA-488 inhibits progression of colorectal cancer via inhibition of the mitogen-activated protein kinase pathway by targeting claudin-2. American Journal of Physiology - Cell Physiology, 2019, 316, C33-C47.	2.1	30
163	The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery, 2019, 165, 476-484.	1.0	11
164	Survival comparison of right and left side nonâ€small cell lung cancer in stage Iâ€“IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis. Thoracic Cancer, 2019, 10, 459-471.	0.8	14
165	mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. International Journal of Clinical Oncology, 2019, 24, 516-525.	1.0	18
166	CD44v6 engages in colorectal cancer progression. Cell Death and Disease, 2019, 10, 30.	2.7	85
167	Impact of treatment modality on clinical outcome in metastatic colorectal cancer patients stratified by metastatic sites. Postgraduate Medicine, 2019, 131, 163-170.	0.9	4

#	Article	IF	Citations
168	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. Clinical Colorectal Cancer, 2019, 18, 141-148.	1.0	19
169	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISEâ€"a global phase III study. Annals of Oncology, 2019, 30, 124-131.	0.6	52
170	Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis. Clinical Colorectal Cancer, 2019, 18, e104-e116.	1.0	34
171	CT-guided percutaneous radiofrequency ablation for lung metastases from colorectal cancer. International Journal of Clinical Oncology, 2019, 24, 288-295.	1.0	27
172	Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of Targeted Chemotherapy. Journal of Gastrointestinal Surgery, 2019, 23, 2144-2150.	0.9	18
173	Implication of primary tumor location for the indication of preoperative chemotherapy in patients with colorectal liver metastases. Hpb, 2019, 21, 405-412.	0.1	13
174	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Annals of Surgery, 2019, 269, 917-923.	2.1	121
175	Clinical and prognostic differences between surgically resected right-sided and left-sided colorectal cancer. Surgery Today, 2020, 50, 267-274.	0.7	14
176	Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology, 2020, 17, 11-32.	12.5	195
177	Colorectal Cancer Metastases to Brain or Bone and the Relationship to Primary Tumor Location: a Population-Based Study. Journal of Gastrointestinal Surgery, 2020, 24, 1833-1842.	0.9	32
178	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta OncolÃ³gica, 2020, 59, 417-426.	0.8	22
179	Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and metaâ€anâ€analysis. Cancer Medicine, 2020, 9, 1044-1057.	1.3	72
180	Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study. International Journal of Colorectal Disease, 2020, 35, 223-232.	1.0	15
181	Utilisation of Adjuvant Chemotherapy and 5-Year Survival Analysis of Prospectively Recorded Cohort Data for Older Adults Versus Younger Adults with Resected Primary Colon Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 988-997.	0.6	0
182	The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. Annals of Surgical Oncology, 2020, 27, 1580-1588.	0.7	38
183	Verifying the M1c category of CRC: analysis of the data from a Japanese multi-institutional database. International Journal of Colorectal Disease, 2020, 35, 125-131.	1.0	7
184	Primary tumour location is an important prognostic factor in colorectal cancer liver metastases following radiofrequency ablation. Clinical Radiology, 2020, 75, 961.e1-961.e9.	0.5	2
185	Nomograms predicting Overall Survival and Cancer-specific Survival for Synchronous Colorectal Liver-limited Metastasis. Journal of Cancer, 2020, 11, 6213-6225.	1.2	18

#	Article	IF	Citations
186	Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer. Pathology and Oncology Research, 2020, 26, 2683-2691.	0.9	6
187	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. Cancer and Metastasis Reviews, 2020, 39, 1143-1157.	2.7	19
188	A Qualitative Transcriptional Signature for Predicting CpG Island Methylator Phenotype Status of the Right-Sided Colon Cancer. Frontiers in Genetics, 2020, 11, 971.	1.1	0
189	Prognostic Factors Involved in the Epithelialâ€“Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 3330.	1.7	5
190	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
191	Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. Scientific Reports, 2020, 10, 19815.	1.6	7
192	Distant Metastasis in Colorectal Cancer Patientsâ€”Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5255.	1.8	38
193	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. Cancers, 2020, 12, 2457.	1.7	3
194	Immune Adaptation of Colorectal Cancer Stem Cells and Their Interaction With the Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 588542.	1.3	15
195	Predictive and Prognostic Factors of Synchronous Colorectal Lung-Limited Metastasis. Gastroenterology Research and Practice, 2020, 2020, 1-11.	0.7	7
196	Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. World Journal of Surgical Oncology, 2020, 18, 98.	0.8	2
197	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. International Journal of Colorectal Disease, 2020, 35, 1513-1527.	1.0	7
198	Quality of Colonoscopy: A Comparison Between Gastroenterologists and Nongastroenterologists. Diseases of the Colon and Rectum, 2020, 63, 980-987.	0.7	12
199	Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports, 2020, 10, 4905.	1.6	41
200	Colorectal cancer statistics, 2020. Ca-A Cancer Journal for Clinicians, 2020, 70, 145-164.	157.7	3,302
201	Role of Genetic Ancestry in 1,002 Brazilian Colorectal Cancer Patients From Barretos Cancer Hospital. Frontiers in Oncology, 2020, 10, 145.	1.3	12
202	Tumor Tissue-Specific Biomarkers of Colorectal Cancer by Anatomic Location and Stage. Metabolites, 2020, 10, 257.	1.3	16
203	Clinicopathologic characteristics of resectable colorectal cancer with mismatch repair protein defects in Chinese population. Medicine (United States), 2020, 99, e20554.	0.4	4

#	Article	IF	Citations
204	A populationâ€based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer. Cancer Medicine, 2020, 9, 5851-5859.	1.3	10
205	Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases. Frontiers in Genetics, 2020, 11, 96.	1.1	18
206	Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Cancer Control, 2020, 27, 107327482090227.	0.7	8
207	Microbiome in Colorectal Cancer: How to Get from Meta-omics to Mechanism?. Trends in Microbiology, 2020, 28, 401-423.	3.5	135
208	Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. BMC Cancer, 2020, 20, 124.	1.1	8
209	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	3.8	9
210	Using machine learning to construct nomograms for patients with metastatic colon cancer. Colorectal Disease, 2020, 22, 914-922.	0.7	7
211	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. Journal of Cancer, 2020, 11, 883-892.	1.2	5
212	Tumor Sidedness Is Associated with Survival in Patients with Synchronous Colorectal Peritoneal Carcinomatosis. Oncology, 2020, 98, 230-236.	0.9	3
213	Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers, 2020, 12, 319.	1.7	141
214	Surgery on primary tumor shows survival benefit in selected stage IV colon cancer patients: A real-world study based on SEER database. Journal of Cancer, 2020, 11, 3567-3579.	1.2	12
215	Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study. Clinical Colorectal Cancer, 2020, 19, 200-208.e1.	1.0	7
216	The prognostic relevance of primary tumor sidedness to surgical treatment for recurrent colon cancer. Surgery Today, 2021, 51, 94-100.	0.7	4
217	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on realâ€life data. International Journal of Cancer, 2021, 148, 296-306.	2.3	27
218	Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clinical Colorectal Cancer, 2021, 20, e53-e60.	1.0	24
219	Impact of Primary Tumor Location on Survival After Curative Resection in Patients with Colon Cancer: A Metaâ€Analysis of Propensity Scoreâ€Matching Studies. Oncologist, 2021, 26, 196-207.	1.9	3
220	Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients. Annals of Surgical Oncology, 2021, 28, 3685-3694.	0.7	3
221	The Role of <i>Fusobacterium nucleatum</i> in Colorectal Carcinogenesis. Pathobiology, 2021, 88, 127-140.	1.9	15

#	Article	IF	Citations
222	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. Oncologist, 2021, 26, 302-309.	1.9	9
223	A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). International Journal of Clinical Oncology, 2021, 26, 399-408.	1.0	5
224	The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status. Annals of Surgery, 2021, 273, 1165-1172.	2.1	33
225	Die Rolle von zytoreduktiver Chirurgie und HIPEC beim Kolonkarzinom. , 2021, , 451-464.		0
226	Impact of Colon Cancer Location on the Prognostic Significance of Nutritional Indexes and Inflammatory Markers. In Vivo, 2021, 35, 1261-1269.	0.6	7
227	The rise of proximal colorectal cancer: a trend analysis of subsite specific primary colorectal cancer in the SEER database. Annals of Gastroenterology, 2021, 34, 559-567.	0.4	6
228	Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 625212.	1.8	4
229	Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
230	A Comparison of Tramadol and Pethidine Analgesia on the Duration of Labour. Disease and Diagnosis, 2021, 10, 1-6.	0.1	0
231	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 307-318.	2.3	17
232	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359.	2.3	758
233	Prognosis of Patients after Oophorectomy for Ovarian Metastases from Colorectal Cancer. Japanese Journal of Gastroenterological Surgery, 2021, 54, 245-252.	0.0	0
234	Association between cigarette smoking and colorectal cancer sidedness: A multi-center big-data platform-based analysis. Journal of Translational Medicine, 2021, 19, 150.	1.8	10
235	Prognostic nomograms for predicting overall survival and cause-specific survival of signet ring cell carcinoma in colorectal cancer patients. World Journal of Clinical Cases, 2021, 9, 2503-2518.	0.3	4
236	Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis. BMC Cancer, 2021, 21, 503.	1.1	1
237	Colon cancer survival differs from right side to left side and lymph node harvest number matter. BMC Public Health, 2021, 21, 906.	1.2	30
238	Explainable artificial intelligence in high-throughput drug repositioning for subgroup stratifications with interventionable potential. Journal of Biomedical Informatics, 2021, 118, 103792.	2.5	10
239	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1705-1713.	3.0	12

#	Article	IF	Citations
240	The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. British Journal of Cancer, 2021, 125, 816-825.	2.9	7
241	Genetic and biological hallmarks of colorectal cancer. Genes and Development, 2021, 35, 787-820.	2.7	159
242	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. Seminars in Oncology, 2021, 48, 119-129.	0.8	4
243	Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Frontiers in Oncology, 2021, 11, 688709.	1.3	5
244	Laparoscopic approach for T4 colon cancer can be associated with poor prognosis in right-sided T4b tumours. European Journal of Surgical Oncology, 2021, 47, 1645-1650.	0.5	3
245	Comparative analysis of clonal evolution among patients with right- and left-sided colon and rectal cancer. IScience, 2021, 24, 102718.	1.9	9
246	PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+Î³Î´ Treg polarization. JCI Insight, 2021, 6, .	2.3	26
247	The Genes Encoding Small Leucine-Rich Proteoglycans Undergo Differential Expression Alterations in Colorectal Cancer, Depending on Tumor Location. Cells, 2021, 10, 2002.	1.8	2
248	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	3.0	25
249	Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2021, 12, 1509-1517.	0.6	3
250	Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location. American Journal of Roentgenology, 2021, 217, 1141-1152.	1.0	3
251	Editorial Comment: Primary Tumor Location Is a Significant Prognostic Factor of Survival After 90Y Radioembolization for Metastatic Colorectal Cancer. American Journal of Roentgenology, 2021, 217, 12-12.	1.0	0
252	Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 559-564.	0.6	6
253	The Validity of a New Edition of Classification for Ovarian Metastasis from Colorectal Cancer. Journal of the Anus, Rectum and Colon, 2021, 5, 40-45.	0.4	2
254	Effect of epidural analgesia on cancer prognosis after colon cancer resection: a single-centre cohort study in Taiwan. BMJ Open, 2020, 10, e036577.	0.8	6
255	Tumour location and efficacy of first-line EGFR inhibitors in wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. ESMO Open, 2019, 4, e000599.	2.0	11
256	Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open, 2020, 5, e000605.	2.0	18
257	Extracellular Vesicle-Transported Long Non-Coding RNA (LncRNA) X Inactive-Specific Transcript (XIST) in Serum is a Potential Novel Biomarker for Colorectal Cancer Diagnosis. Medical Science Monitor, 2020, 26, e924448.	0.5	12

#	Article	IF	Citations
258	Characteristics of Differently Located Colorectal Cancers Support Proximal and Distal Classification: A Population-Based Study of 57,847 Patients. PLoS ONE, 2016, 11, e0167540.	1.1	55
259	Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? - Lessons from 10 yearsâ€™ experience. Oncotarget, 2017, 8, 100791-100800.	0.8	18
260	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget, 2017, 8, 105749-105760.	0.8	41
261	Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database. Oncotarget, 2015, 6, 33935-33943.	0.8	39
262	Colorectal cancer genomics and designing rational trials. Annals of Translational Medicine, 2018, 6, 159-159.	0.7	19
263	Hyperuricemia at The Time Of Diagnosis is a Factor for Poor Prognosis in Patients With Stage II and III Colorectal Cancer (Uric Acid and Colorectal Cancer). Asian Pacific Journal of Cancer Prevention, 2017, 18, 485-490.	0.5	6
264	Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. World Journal of Gastroenterology, 2016, 22, 4250.	1.4	8
265	RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. Oncology Reports, 2020, 43, 1853-1862.	1.2	15
266	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean Journal of Internal Medicine, 2019, 34, 165-177.	0.7	20
267	Right versus left-sided colon cancer: Is it time to consider these as different diseases?. AIMS Medical Science, 2018, 5, 303-315.	0.2	2
268	Survival Benefit of Palliative Primary Tumor Resection Based on Tumor Location in Patients with Metastatic Colorectal Cancer: A Single-center Retrospective Study. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2020, 76, 17-27.	0.2	3
269	Clinical-Pathological Characteristics of Colorectal Carcinoma and Factors Influence 2-Years Survival among Patients Attending Ocean Road Cancer Institute Dar es Salaam Tanzania. Open Journal of Gastroenterology, 2019, 09, 59-72.	0.1	1
270	Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy. World Journal of Gastrointestinal Oncology, 2018, 10, 431-438.	0.8	3
271	Primary tumor location and survival in colorectal cancer: A retrospective cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 405-423.	0.8	11
272	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 2022, 114, 427-435.	3.0	24
273	National trends in hospitalizations among patients with colorectal cancer in the United States. Baylor University Medical Center Proceedings, 2022, 35, 153-155.	0.2	2
274	Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer. Farmakoekonomika, 2021, 14, 291-298.	0.4	0
275	A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI â€“ Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. Oncology, 2021, , 1-11.	0.9	1

#	Article	IF	Citations
276	Clinicoepidemiological Study and Survival Analysis of Right versus Left Sided Colon Cancer Patients. The Egyptian Journal of Hospital Medicine, 2017, 69, 1723-1737.	0.0	0
277	Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer. Meditsinskiy Sovet, 2018, , 50-55.	0.1	4
278	Multidisciplinary Treatment of Liver Metastasis from Colorectal Cancer to Create Novel Evidences. Japanese Journal of Gastroenterological Surgery, 2019, 52, 390-403.	0.0	0
279	Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer. Current Cancer Drug Targets, 2019, 19, 534-550.	0.8	1
280	Systemic Therapy for Colorectal Cancer Liver Metastases: Sorting Through the Options. , 2020, , 185-203.		0
281	Clinicopathological Study of Resected Liver Metastasis from the View of the Colon Cancer Location, Right or Left Sidedness. Nihon Daicho Komonbyo Gakkai Zasshi, 2020, 73, 151-156.	0.1	0
282	Prognosis of distal pancreatic cancers controlled by stage. Experimental and Therapeutic Medicine, 2020, 20, 1091-1097.	0.8	8
283	Factors associated with the survival of colorectal cancer in Mexico. Intestinal Research, 2020, 18, 315-324.	1.0	8
284	The Effect of Tumor Sideness and Mutational Status on First Line Treatment Response and Survival in The Patients with Metastatic Colorectal Cancer. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2020, 30, 197-206.	0.1	0
285	PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. PLoS ONE, 2020, 15, e0243997.	1.1	0
288	IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2020, 33, e1524.	0.5	6
289	Short- and long-term outcomes of laparoscopic segmental left colectomy for splenic flexure colon cancer: comparison with propensity score matching. Annals of Surgical Treatment and Research, 2021, 101, 274.	0.4	1
290	Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study. Anticancer Research, 2021, 41, 5693-5702.	0.5	3
293	ESMO World Congress on Gastrointestinal Cancer. P and T, 2017, 42, 586-589.	1.0	0
294	Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. American Journal of Cancer Research, 2018, 8, 2337-2345.	1.4	5
295	Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection. Acta Biomedica, 2020, 92, e2021061.	0.2	0
296	Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives. Journal of Clinical and Translational Research, 2021, 7, 511-522.	0.3	5
297	Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. Cancers, 2021, 13, 5824.	1.7	4

#	Article	IF	Citations
299	TP53 Gain-of-Function and Nonâ€“Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2022, 40, 171-179.	0.8	33
301	Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3007-3014.	1.2	2
302	Is precision medicine for colorectal liver metastases still a utopia? New perspectives by modern biomarkers, radiomics, and artificial intelligence. World Journal of Gastroenterology, 2022, 28, 608-623.	1.4	9
303	Comparison of Resected Malignant Tumors of the Right- and Left-Sided Colonâ€”Is There a Difference?. Indian Journal of Surgery, 0, , 1.	0.2	2
304	Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer. Current Oncology, 2022, 29, 1370-1389.	0.9	2
305	Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patientâ€™s Stratification. Frontiers in Oncology, 2022, 12, 856575.	1.3	13
306	Chemoprevention for Colorectal Cancers: Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers?. Digestive Diseases and Sciences, 2022, , 1.	1.1	3
307	Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. Nature Communications, 2022, 13, 1618.	5.8	23
308	Diabetes and Risks of Right-Sided and Left-Sided Colon Cancer: A Meta-Analysis of Prospective Cohorts. Frontiers in Oncology, 2022, 12, 737330.	1.3	6
309	Pathological Features and Prognostication in Colorectal Cancer. Current Oncology, 2021, 28, 5356-5383.	0.9	48
310	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer, 2022, 22, 394.	1.1	7
320	Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location. Journal of Gastroenterology, 2022, 57, 476-485.	2.3	2
322	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. Journal of Clinical and Translational Research, 2021, 7, 771-785.	0.3	1
323	Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.. American Journal of Cancer Research, 2022, 12, 490-503.	1.4	0
324	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Targeted Oncology, 2022, , 1.	1.7	1
325	Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases. Radiology Imaging Cancer, 2022, 4, e210105.	0.7	3
326	Associations of Complete Blood Count Parameters with Disease-Free Survival in Right- and Left-Sided Colorectal Cancer Patients. Journal of Personalized Medicine, 2022, 12, 816.	1.1	4
327	Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases. International Journal of Molecular Sciences, 2022, 23, 6091.	1.8	6

#	Article	IF	Citations
328	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. British Journal of Cancer, 2022, 127, 957-967.	2.9	6
329	Blood-Cell-Based Inflammatory Markers as a Useful Tool for Early Diagnosis in Colorectal Cancer. Frontiers in Medicine, 0, 9, .	1.2	10
330	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. Journal of Clinical Oncology, 2022, 40, 2878-2888.	0.8	24
331	Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer. ATLA Alternatives To Laboratory Animals, 2022, 50, 282-292.	0.7	6
332	Racial Disparities in Colorectal Cancer Care for Black Patients: Barriers and Solutions. American Surgeon, 2022, 88, 2823-2830.	0.4	3
333	Epidemiology and risk factors for metastatic colorectal disease. , 2023, , 1-17.		0
334	Identifying the tumor location-associated candidate genes in development of new drugs for colorectal cancer using machine-learning-based approach. Medical and Biological Engineering and Computing, 0, , .	1.6	0
335	Nomograms predicting cancer-specific survival for stage IV colorectal cancer with synchronous lung metastases. Scientific Reports, 2022, 12, .	1.6	3
336	Embryologic Origin of the Primary Tumor and RAS Status Predict Survival after Resection of Colorectal Liver Metastases. Medicina (Lithuania), 2022, 58, 1100.	0.8	0
337	Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis. Cancer Treatment and Research Communications, 2022, 33, 100632.	0.7	0
339	Endoscopic polypectomy for malignant polyps: Should tumor location (right versus left side) guide clinical decisions?. Surgery, 2023, 173, 674-680.	1.0	0
340	Timeâ€varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a populationâ€based study and metaâ€analysis. International Journal of Cancer, 0, , .	2.3	2
341	The prognostic impact of BMI on colorectal cancer is stratified by tumor location. Frontiers in Oncology, 0, 12, .	1.3	1
342	Initial Systemic Chemotherapy for Metastatic Colorectal Cancer. , 2022, , 279-286.		0
343	Current Targeted Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 1702.	1.8	22
344	New developments in targeted therapy for metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211485.	1.4	8
345	NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer. Clinical Cancer Research, 2023, 29, 1741-1750.	3.2	2
346	Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy. Cancers, 2023, 15, 613.	1.7	5

#	Article	IF	Citations
347	Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÃš-1 and Phase II VISNÃš-2 Randomized Trials. Clinical Colorectal Cancer, 2023, 22, 222-230.	1.0	1
348	Colorectal cancer statistics, 2023. Ca-A Cancer Journal for Clinicians, 2023, 73, 233-254.	157.7	400
349	Validation of algorithms to identify colorectal cancer patients from administrative claims data of a Japanese hospital. BMC Health Services Research, 2023, 23, .	0.9	1
350	A Belgian Population-Based Study Reveals Subgroups of Right-sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer. Oncologist, 2023, 28, e331-e340.	1.9	1
360	Biomarkers in Colon Cancer Metastasis. , 2023, , 1-23.		0